Display options
Cite
Lasierra-Cirujeda J, Coronel P, Aza M, et al. Use of sulodexide in patients with peripheral vascular disease. J Blood Med. 2010;1:105-15doi: 10.2147/JBM.S10558.
Lasierra-Cirujeda, J., Coronel, P., Aza, M., & Gimeno, M. (2010). Use of sulodexide in patients with peripheral vascular disease. Journal of blood medicine, 1105-15. https://doi.org/10.2147/JBM.S10558
Lasierra-Cirujeda, J, et al. "Use of sulodexide in patients with peripheral vascular disease." Journal of blood medicine vol. 1 (2010): 105-15. doi: https://doi.org/10.2147/JBM.S10558
Lasierra-Cirujeda J, Coronel P, Aza M, Gimeno M. Use of sulodexide in patients with peripheral vascular disease. J Blood Med. 2010;1:105-15. doi: 10.2147/JBM.S10558. Epub 2010 Jun 15. PMID: 22282689; PMCID: PMC3262318.
Copy Download .nbib Format: NLM
Share it on

J Blood Med. 2010;1:105-15. doi: 10.2147/JBM.S10558. Epub 2010 Jun 15.

Use of sulodexide in patients with peripheral vascular disease.

Journal of blood medicine

J Lasierra-Cirujeda, P Coronel, Mj Aza, M Gimeno

Affiliations

  1. CM Hematológico SC, Logroño, La Rioja;

PMID: 22282689 PMCID: PMC3262318 DOI: 10.2147/JBM.S10558

Abstract

Sulodexide is a highly purified glycosaminoglycan containing a combination of heparan sulfate with affinity for antithrombin III and dermatan sulfate with affinity for heparin cofactor II. This antithrombotic and antithrombin activity is of great pharmacologic interest and makes sulodexide a suitable drug for the prophylaxis and treatment of arterial and venous peripheral diseases. In arterial pathology, changes in the Winsor Index, improvement in peripheral blood flow, and reduction in pain-free walking distance confirm that treatment with oral sulodexide is effective. Lipid components linked to the genesis of peripheral vascular processes, including triglycerides, total cholesterol, and low-density lipoprotein fractions, as well as plasma and blood viscosity, are reduced by the administration of sulodexide, whereas the high-density lipoprotein fraction increases. Sulodexide inhibits aggregation and adhesion of platelets at the level of the vascular wall, reduces plasma fibrinogen concentrations, reduces plasminogen activator inhibitor-1, and increases tissue plasminogen activator, as well as systemic fibrinolytic and thrombolytic activity, thereby demonstrating efficacy in the treatment of thromboembolic disease. There is no interaction between sulodexide and other drugs used as long-term treatment for peripheral vascular disease. It is well tolerated, and the adverse reactions described after oral administration are related mainly to transient gastrointestinal intolerance, ie, nausea, dyspepsia, and minor bowel symptoms. Sulodexide may become the treatment of choice when dealing with vascular diseases and their complications, as well as for the prevention of venous thromboembolic disease, being particularly indicated in elderly patients, due to its good tolerability and ease of management.

Keywords: efficacy; peripheral vascular disease; safety; sulodexide; venous thromboembolism

References

  1. Microvasc Res. 1973 Mar;5(2):167-79 - PubMed
  2. Vasc Health Risk Manag. 2008;4(3):637-45 - PubMed
  3. Thromb Res. 1986 Jan 1;41(1):23-31 - PubMed
  4. Semin Thromb Hemost. 1988 Jan;14(1):18-27 - PubMed
  5. Arzneimittelforschung. 1985;35(10):1517-9 - PubMed
  6. Thromb Haemost. 1992 Oct 5;68(4):424-7 - PubMed
  7. Eur Heart J. 2002 Jul;23(13):1057-65 - PubMed
  8. Blood. 1985 Jan;65(1):198-201 - PubMed
  9. Thromb Res. 1984 Apr 1;34(1):81-6 - PubMed
  10. Curr Vasc Pharmacol. 2009 Jul;7(3):394-413 - PubMed
  11. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):303-7 - PubMed
  12. Clin Ter. 1987 Jan 15;120(1):25-31 - PubMed
  13. Thromb Haemost. 1992 Feb 3;67(2):203-8 - PubMed
  14. Monogr Atheroscler. 1986;14:215-21 - PubMed
  15. Curr Med Res Opin. 1997;13(10):573-82 - PubMed
  16. Curr Med Res Opin. 1993;13(2):96-108 - PubMed
  17. J Am Coll Cardiol. 1994 Jan;23(1):27-34 - PubMed
  18. Thromb Haemost. 2002 Jun;87(6):947-52 - PubMed
  19. Farmaco Prat. 1986 Feb;41(2):67-74 - PubMed
  20. Med Res Rev. 1998 Jan;18(1):1-20 - PubMed
  21. Semin Thromb Hemost. 1998;24(2):127-38 - PubMed
  22. Clin Ter. 1986 May 15;117(3):223-31 - PubMed
  23. Atherosclerosis. 1986 May;60(2):141-9 - PubMed
  24. J Lab Clin Med. 1991 Feb;117(2):122-30 - PubMed
  25. Arzneimittelforschung. 1989 Jan;39(1):15-20 - PubMed
  26. Curr Med Res Opin. 1991;12(5):325-31 - PubMed
  27. Wien Klin Wochenschr. 1993;105(11):309-13 - PubMed
  28. Arzneimittelforschung. 1985;35(10):1513-6 - PubMed
  29. Atherosclerosis. 1990 Apr;81(3):233-43 - PubMed
  30. Angiology. 1989 Apr;40(4 Pt 1):255-9 - PubMed
  31. Drugs Exp Clin Res. 1992;18(5):189-95 - PubMed
  32. Eur J Vasc Endovasc Surg. 2007 Apr;33(4):442-50 - PubMed
  33. Vnitr Lek. 1993 Jun;39(6):575-80 - PubMed
  34. Arch Pathol. 1969 Aug;88(2):99-105 - PubMed
  35. Vasc Health Risk Manag. 2009;5:693-704 - PubMed
  36. Int J Clin Lab Res. 1992;22(3):179-84 - PubMed
  37. Microvasc Res. 1976 Mar;11(2):203-15 - PubMed
  38. G Clin Med. 1985 Jan-Feb;66(1-2):37-45 - PubMed
  39. Curr Med Res Opin. 1993;13(2):87-95 - PubMed
  40. Semin Thromb Hemost. 1994;20(3):281-92 - PubMed
  41. Zentralbl Allg Pathol. 1989;135(6):517-30 - PubMed
  42. Vasc Health Risk Manag. 2009;5:819-31 - PubMed
  43. Drugs. 2007;67(18):2681-96 - PubMed
  44. Angiology. 2004 May-Jun;55(3):243-9 - PubMed
  45. Biomed Biochim Acta. 1989;48(9):721-5 - PubMed
  46. Cardiovasc Drug Rev. 2006 Fall-Winter;24(3-4):214-26 - PubMed
  47. J Int Med Res. 1985;13(1):40-7 - PubMed
  48. Clin Ter. 1982 Jun 30;101(6):603-14 - PubMed
  49. Angiology. 2006 Jan-Feb;57(1):53-64 - PubMed
  50. Thromb Res. 1984 Nov 1;36(3):245-57 - PubMed
  51. Thromb Res. 1994 Jun 1;74(5):463-75 - PubMed
  52. Atherosclerosis. 1992 Jun;94(2-3):135-46 - PubMed
  53. Semin Thromb Hemost. 1993;19 Suppl 1:49-57 - PubMed
  54. J Int Med Res. 1992 Feb;20(1):45-53 - PubMed

Publication Types